Patients at various stages of cardiac, renal, and metabolic diseases should be included in future trials to ensure that the existing evidence is generalizable. Results of ongoing and future randomized controlled trials will undoubtedly broaden the clinical indications across a wide range of patient populations, enabling us to discover and unlock more benefits of SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is metabolic disease.